Patent search ap:("INTRA-CELLULAR THERAPIES Page INC.") AND inv:"Robert E Davis"

1.

发明授权
Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders 有权

公开(公告)号：US12122792B2

公开(公告)日：2024-10-22

申请号：US18240951

申请日：2023-08-31

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng Li , Robert E Davis , Kimberly Vanover

IPC: A61K31/4985 , C07D471/22 , C07D487/22 , C07D519/00

CPC classification number: C07D519/00

Abstract: The invention relates to pharmaceutical compositions comprising the compound of Formula I,

and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

2.

发明授权
4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders 有权

公开(公告)号：US11753419B2

公开(公告)日：2023-09-12

申请号：US17757212

申请日：2020-12-10

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng Li , Robert E Davis , Kimberly Vanover

IPC: A61K31/4985 , C07D471/22 , C07D487/22 , C07D519/00

CPC classification number: C07D519/00

Abstract: The invention relates to a particular substituted heterocycle fused gamma carboline, the compound of Formula I,

and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

Patent Agency Ranking